<DOC>
	<DOCNO>NCT00046527</DOCNO>
	<brief_summary>Paclitaxel ( Taxol , Bristol-Meyers Squibb ) show effective metastatic breast cancer , well cancer . Because Taxol formulation paclitaxel dissolve Cremophor , organic solvent contain castor oil , ethanol , prolong intravenous administration time require ; solvent cause hypersensitivity reaction , premedication schedule require . ABI-007 new anticancer medication contain active ingredient Taxol , paclitaxel , formulate protein-stabilized material suspend salt water administer intravenously . The time administration reduce , dose paclitaxel high safe Taxol , premedication require . This study determine efficacy new formulation paclitaxel , compare Taxol , patient metastatic breast cancer . This open label comparative study , patient randomly assign receive either Taxol ABI-007 form paclitaxel , know medication receiving . Treatment repeat every three week unless adverse event treatment failure require discontinuing study medication .</brief_summary>
	<brief_title>Study ABI-007 Taxol Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>Taxol ( Bristol-Meyers Squibb ) active carcinoma ovary , breast , lung , esophagus head neck . A number dose schedule Taxol test breast cancer . Initial trial use 250 mg/m2 continuous infusion 24 hour . Subsequently , short infusion Taxol three hour test dose 175 mg/m2 , response rate 30 % -40 % . Phase II study use high dos Taxol 200-250 mg/m2 response rate 56 % metastatic breast cancer patient . However , dos , significant toxicity occur , include neuropathy . There median granulocyte count nadir 100-200 cells/mm3 majority course administer . There also significant side effect associate hypersensitivity Taxol vehicle , Cremophor-EL . These hypersensitivity reaction require premedication schedule include corticosteroid , H2 antagonist antihistamine . Abraxis BioScience test reformulate form paclitaxel without Cremophor . This formulation protein-stabilized , nanoparticle suspension paclitaxel human serum albumin normal saline . The potential advantage formulation : - Higher tolerated dos , great efficacy - Longer drug persistence tumor result nanoparticle formulation - Reduced infusion time - Reduced risk hypersensitivity require premedication schedule - More rapid distribution paclitaxel tissue base pharmacokinetic data This study evaluate ABI-007 , compare Taxol , patient metastatic breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Patients eligible trial : Female , nonpregnant , nonlactating , , childbearing potential , negative serum pregnancy test , use approve contraception Sixteen year age old Histologically cytologically confirm breast cancer ( stage III IV ) evidence inoperable local recurrence metastasis , measurable disease If patient receive taxane therapy adjuvant he/she relapse within one year complete adjuvant taxane No malignancy present within past 5 year , except nonmelanoma skin cancer , cervical intraepithelial neoplasia insitu cervical cancer Suitable candidate paclitaxel therapy Hematology level baseline : absolute neutrophil count least 1500 cells/mm3 ; platelet count least 100,000 cells/mm3 ; hemoglobin least 9 g/dL Chemistry level baseline : AST ALT less equal 2.5 x upper limit normal , evidence liver metastasis ; total bilirubin less equal 1.5 mg/dL ; creatinine le equal 2 mg/dL ; alkaline phosphatase less equal 5 x upper limit normal , unless bone metastasis liver metastasis Expected survival least 12 week Patient his/her representative sign informed consent form</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2004</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Taxol</keyword>
	<keyword>Taxane</keyword>
</DOC>